Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03402295

Acronym

GBRAM003r

Enrollment

311

Registered

2018-01-18

Start date

2009-06-15

Completion date

2017-10-15

Last updated

2018-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effects of Chemotherapy, Multiple Myeloma

Brief summary

This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.

Detailed description

The primary aim was observe response rate after 4 induction cycles.

Interventions

DRUGBortezomib, cyclophosphamide, thalidomide, dexamethasone

Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Retrospectively compared two different groups of treatments

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* multiple myeloma newly diagnose elegible to autologous transplantation Patients submitted to ctd or vcd Myeloma patients newly diagnose \>18yo

Exclusion criteria

* other chemotherapy induction protocol

Design outcomes

Primary

Measure	Time frame	Description
Response rate better than very good partial response after 4 induction cycles	Response rate after induction phase - at the end of cycle 4- (28 days each cycle)- time frame trough study completion	The primary outcome is to observe the difference response rate between VCD and CTD induction myeloma elegible patient

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026